Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease

NCT00529204 on ClinicalTrials.gov · last registry update 2017-06-20

Stopped early, having planned 1 participants. The sponsor logged completion for July 2009. Primary outcome, as filed: Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy. exenatide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P2
Drug: exenatide
Bydureon, Byetta
Sponsor: University of California, Davis
Sponsor type: Other
Enrollment: 1
Started: 2007-10
Primary completion: 2009-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Reduction in Serum ALT From Baseline to 24 Weeks of Exenatide Therapy

Conditions studied

Diabetes Complications · Fatty Liver

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.